Axela introduces assay kits for validating tumour markers

24 April 2009

Axela Inc. has launched nine plate based tumour marker assays. Available in high performance ELISA format they have been designed for stand alone use or to simplify the transition to automated dotLab assays. Used in conjunction with Axela’s panelPlus biomarker menu (available for the dotLab system this summer) this unique approach has the potential to significantly transform the speed with which putative biomarkers can be validated.

The following RUO (research use only) immunoassay kits for quantitative determination of cancer antigens are available immediately: alpha-fetoprotein (AFP); carcinoembroyonic antigen (CEA); CA125; CA15-3; CA 19-9; PSA; free PSA (f-PSA); free beta subunit of human chorionic gonadotropin (free beta-hCG) and beta-2 Microglobulin (B2MG).

In order to facilitate assay validation and simplify multiplexing the panelPlus biomarker menu will incorporate the same capture reagents as these ELISA kits. The ability to observe multiple analytes in real-time provides a wider detection range than previously available.

Offering significant advantages over end point techniques, the dotLab System allows creation of highly targeted and flexible biomarker panels using these self addressing reagents. Scientists will be able to select from the menu of analytes, and incorporate their own proprietary reagents using the panelPlus address kit. Novel discoveries can be compared directly to markers with known utility without increasing sample volume requirements.

Axela is extending the versatility of the dotLab System by providing biomarker assay and validation tools that complement its ability to perform interaction studies, expression monitoring and analysis of cancer autoantibodies.

These new, easy to use, robust ELISAs will help researchers quantitate cancer biomarkers in basic and clinical research settings and will be followed by a selection of cardiology and infectious disease targets. They are available through VWR Life Science in North America and Axela in Europe

Bookmark this page

Your browser does not support inline frames or is currently configured not to display inline frames.	Your browser does not support inline frames or is currently configured not to display inline frames. Axela introduces assay kits for validating tumour markers 24 April 2009 Axela Inc. has launched nine plate based tumour marker assays. Available in high performance ELISA format they have been designed for stand alone use or to simplify the transition to automated dotLab assays. Used in conjunction with Axela’s panelPlus biomarker menu (available for the dotLab system this summer) this unique approach has the potential to significantly transform the speed with which putative biomarkers can be validated. The following RUO (research use only) immunoassay kits for quantitative determination of cancer antigens are available immediately: alpha-fetoprotein (AFP); carcinoembroyonic antigen (CEA); CA125; CA15-3; CA 19-9; PSA; free PSA (f-PSA); free beta subunit of human chorionic gonadotropin (free beta-hCG) and beta-2 Microglobulin (B2MG). In order to facilitate assay validation and simplify multiplexing the panelPlus biomarker menu will incorporate the same capture reagents as these ELISA kits. The ability to observe multiple analytes in real-time provides a wider detection range than previously available. Offering significant advantages over end point techniques, the dotLab System allows creation of highly targeted and flexible biomarker panels using these self addressing reagents. Scientists will be able to select from the menu of analytes, and incorporate their own proprietary reagents using the panelPlus address kit. Novel discoveries can be compared directly to markers with known utility without increasing sample volume requirements. Axela is extending the versatility of the dotLab System by providing biomarker assay and validation tools that complement its ability to perform interaction studies, expression monitoring and analysis of cancer autoantibodies. These new, easy to use, robust ELISAs will help researchers quantitate cancer biomarkers in basic and clinical research settings and will be followed by a selection of cardiology and infectious disease targets. They are available through VWR Life Science in North America and Axela in Europe Bookmark this page Your browser does not support inline frames or is currently configured not to display inline frames. To top	Your browser does not support inline frames or is currently configured not to display inline frames.